Related Experiment Video

Updated: Jul 13, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K

A New Chapter in Neoadjuvant Therapy for High-risk Prostate Cancer?

Ulrich Krafft1, Boris A Hadaschik1, Katharina Lückerath2

  • 1Department of Urology, University Hospital Essen, University Duisburg-Essen, Essen, Germany; West German Cancer Center, University Dusiburg-Essen, University Hospital Essen, Germany.

European Urology
|October 13, 2023
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

487
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.4K

Related Experiment Videos

Last Updated: Jul 13, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

487
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.4K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K

Articles linked to this work by shared authors, journal, and citation graph.

A Phase 2, Open-Label, Randomized Controlled Trial Evaluating Safety and Efficacy of Dose-Intensified Versus Standard Dosing Regimens of [177Lu]Lu-PSMA-597 in mCRPC (OPTIMAL-PSMA).

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Done EAZY: An Automated Procedure for 89Zr-Radiolabeling and Size-Exclusion Chromatography Purification of Nanoliposomal Anticancer Therapeutics.

Molecular pharmaceutics·2026

Tumor anatomy predictors of mic and trifecta achievement in robot-assisted partial nephrectomy: a multicenter analysis stratified by PADUA score.

Journal of robotic surgery·2026

Perioperative Apalutamide in High-Risk Localized Prostate Cancer.

The New England journal of medicine·2026

Radiopharmaceutical Therapy Meets Radiobiology: Implications for Trial Design and DNA Repair Inhibitor Combinations.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Hemorrhage in Robot-assisted Partial Nephrectomy: A Multicentric, Retrospective Analysis of Blood Transfusion and Bleeding Requiring Intervention in 3726 Cases.

European urology open science·2026

Why Look Further When the Solution Is in Front of You - or Is It? The Value of Confirmatory PSA in Prostate Cancer Screening.

European urology·2026

Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial.

European urology·2026

Hereditary Renal Cancer Syndromes: Redefining Clinical Management in the Era of Precision Medicine.

European urology·2026

PSMA Radio-guided Surgery to Identify Lymph Node Metastases in Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Phase 2 Prospective Study.

European urology·2026

EORTC 2238 DE-ESCALATE: Revisiting Intermittent Maximal Androgen Blockade in Metastatic Hormone-sensitive Prostate Cancer.

European urology·2026

Influence of Adverse Pathologic Features on Potential Benefit of Hormone Therapy Use with Postoperative Radiotherapy in Recurrent Prostate Cancer: An Individual Patient Data Meta-analysis.

European urology·2026

A Multimodal Graph Neural Network Based on MRI Radi-omics for Prognostic Prediction in Locally Advanced Cervical Squamous Cell Carcinoma.

Cancer control : journal of the Moffitt Cancer Center·2026

Integrating efficacy and safety profile in advanced HCC: A network meta-analysis of first-line systemic therapies.

JNCI cancer spectrum·2026

Outcomes That Matter in Gastrointestinal Cancer Care: A Focus Group Study of Patient-Centred Outcomes Identified by Patients and Care Partners.

Health expectations : an international journal of public participation in health care and health policy·2026

Nicotinamide Metabolism Constrains Memory CD8+ T Cell Formation Through a Putative HS1BP3-SIRT1-FOXO3-BCL6 Axis.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

GLP-1 receptor agonist therapy is associated with increased symptomatic remission in ulcerative colitis: a matched cohort study.

Inflammatory bowel diseases·2026

Modulating immune toxicity in ulcerative colitis using a small molecule RAB27A inhibitor.

Inflammatory bowel diseases·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us